Drug Profile
BAY 1830839
Alternative Names: BAY-1830839Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Bayer
- Class 3-ring heterocyclic compounds; Amides; Amines; Antineoplastics; Antirheumatics; Ethers; Imidazoles; Morpholines; Quinazolines; Small molecules
- Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
- No development reported Diffuse large B cell lymphoma; Rheumatoid arthritis
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Germany (PO, Tablet)
- 28 Aug 2023 No recent reports of development identified for preclinical development in Diffuse large B cell lymphoma in Germany
- 11 May 2022 Bayer completes a phase I trial in Healthy volunteers in Germany (PO) (NCT03965728)